Introduction
============

For higher efficiency and fewer side effects, aerosol medications are preferred for obstructive airway diseases.[@b1-copd-13-879] However, the most serious limitation is patient skill in using the device. The incorrect use of aerosol devices can lead to poor disease control.[@b2-copd-13-879]--[@b4-copd-13-879] Therefore, patients must use them correctly for successful pharmacological action. For these reasons, training the patient on how to use inhaler devices correctly is very important, as stated by the clinical practice guidelines for asthma and COPD, the European Respiratory Society, and the International Society for Aerosols in Medicine.[@b5-copd-13-879]--[@b7-copd-13-879]

Several studies showed that most patients did not handle inhaler devices properly.[@b8-copd-13-879]--[@b13-copd-13-879] Moreover, it has been reported that health care professionals who prescribe or supervise patients' use and skills had poor knowledge and skills regarding aerosol use.[@b14-copd-13-879]--[@b19-copd-13-879] Undoubtedly, when the health care professionals are uncertain and have questionable skills on how to use aerosol devices, the patient definitely cannot be expected to use them properly. In addition, the pharmacist is the last line of defense before patients attempt to self-administer medication, as the pharmacist plays a significant role in patient education; however, there is a paucity of literature regarding this issue.

According to the report of the Ministry of Health in Iraq, primary health care centers were visited by approximately 230,000 asthmatic patients in 2013 and approximately 200,000 patients per year are either hospitalized or treated in an emergency room.[@b20-copd-13-879] Moreover, a recent study has found that a substantial proportion of patients with asthma or COPD are using their inhaler incorrectly.[@b21-copd-13-879] Most of pharmacists' knowledge is gained from formal study or practice. In Iraq, colleges of pharmacy (government or private universities) offer a bachelor's degree in pharmaceutical sciences which enables the graduates to work as a pharmacist (in government, private or both sectors). On reviewing the pharmacy curriculum, it was found that the clinical pharmacy and therapeutics subjects were studied over 2 years (4th and 5th year students, respectively). Clinical pharmacy subject has 3 h credits (2 h theoretical and 1 h practical per semester) while therapeutics has 5 h credits (theoretical only). Asthma and COPD topics have only 3 h slots only (4th year students). In addition, objective structured clinical examination (OSCE) is not offered in the curriculum of these colleges. Moreover, guidelines on how to use aerosol medications are not even included in the textbooks of these colleges.

Furthermore, pharmacists' knowledge of aerosol medications clearly affects patient response to medication and other pharmaceutical care practice. Additionally, patients seeking advice, treatment, and reassurance should receive the correct information and guidance regarding their medications during patient-centered communication with the pharmacist. Therefore, the aims of this study were to develop and validate Knowledge of Aerosol Tool (KAT) among registered and unregistered pharmacists and to assess the pharmaceutical care practice among registered pharmacists.

Methods
=======

Participants and study design
-----------------------------

An observational cross-sectional study was carried out between November 2016 and April 2017 in Baghdad, the capital of Iraq. Baghdad city has two large district areas named Al-Kharkh and Al-Rusafa. Random cluster sampling method was used to select three areas from each. All retail pharmacies from those areas were considered eligible for participation in the study. All eligible pharmacies were visited by the researcher. Pharmacists declining participation at this initial contact were excluded from the study. Pharmacists deferring until a later date for reasons of inconvenience received two additional visits only; deferment at this time excluded the pharmacist from study. All participants provided written informed consent prior to participation in this study. All personal information collected was considered confidential. The study protocol was approved by the Scientific Committee of Al-Rafidain University Collage, Baghdad, Iraq.

The study comprised of three sections. The first section involved background and demographic information. The second and the third sections were KAT questionnaire and pharmaceutical care practice questionnaire.

Instruments and measurements
----------------------------

The KAT is a 24 multiple-choice item tool in English language with two subscales designed to measure the knowledge of aerosol administration technique and aerosol medicine use with a total score ranging from 0 to 24. A higher score means more knowledge. The KAT questionnaire has two unrelated subscales. Each subscale has 12 items (score ranging from 0 to 12). Then, arbitrarily, two groups were generated: low (range 0--5 points) and high (range 6--12 points) levels for each subscale. Hence, the total lowest score of KAT for adequate (or high) knowledge will be 12. Thus, a cutoff point of 12 was chosen to discriminate between high and low levels. The KAT questionnaire was developed, modified, and compiled from previous reports on comprehensive assessment of aerosol knowledge regarding diverse inhaler devices and common medicine used in Iraq.[@b1-copd-13-879],[@b22-copd-13-879],[@b23-copd-13-879] In addition, pharmaceutical care practice questionnaire was modified from previous report to measure the registered pharmacists care practice.[@b24-copd-13-879] It is 4-point Likert type scale (Never, score 1; Always, score 4) with a total score ranging from 5 to 20. Higher score means higher practice.

Sample size
-----------

A recommendation suggested that at least five subjects per item are needed to evaluate the reliability and validity of KAT questionnaire.[@b25-copd-13-879] Therefore, 120 participants were needed for the purpose of validation. Doubling the sample size, with an additional 30% as drop out, was considered necessary for the study to overcome erroneous results and increase the reliability of the conclusions. With this number of participants, it would be possible to discriminate between high and low correlations.[@b26-copd-13-879] Only 195 registered pharmacists (pharmacists who graduated from college of pharmacy and members of the Syndicate of Iraqi Pharmacists \[SIP\]) were accepted to be involved in this study and completed the questionnaire. Twenty five participants from the sample population were randomly selected for test--retest reliability within 1--2 weeks and not included in the final sample study. During the registration meeting governed by the SIP for unregistered pharmacists (pharmacists newly graduated from college of pharmacy and not members of SIP), a comparable sample (N=170) was selected randomly.

Validation and reliability
--------------------------

### Face validity

Face validity is the capacity of an item to measure the construct that it proposes to measure.[@b27-copd-13-879] Five experts in the pharmacy field were invited in order to test the degree of difficulty, clarity, appropriateness, and comprehensiveness of the questionnaire items and to provide feedback and judge the face validity of KAT questionnaire.

### Reliability

The internal consistency of KAT questionnaire was evaluated using Cronbach's alpha with a minimum acceptable criterion above 0.50. The corrected item total correlations between the scales and their corresponding items were assessed with a minimum acceptable correlation of 0.20.[@b28-copd-13-879] Pearson's correlation coefficient was used to evaluate test--retest reliability.[@b25-copd-13-879]

Statistical analysis
--------------------

Percentages, frequencies, and mean ± SD were used when applicable. The significance level was set at a *P*-value less than 0.05 using Predictive Analytics Software version 19.0. The chi square, Mann--Whitney *U*, and Kruskal--Wallis tests were used to evaluate the association and differences when applicable. The statistical analysis of the validation processes included assessing reliability (Cronbach's alpha and test--retest) and item analysis.

Results
=======

Out of a total of 312 registered pharmacists receiving the questionnaire, only 170 agreed to participate in this study (total response 54.49%). The total sample for validation study was 340 (170 registered pharmacists and 170 unregistered pharmacists), in addition to 25 registered pharmacists for test--retest analysis.

Sociodemographic
----------------

The demographic characteristics of the study population are presented in [Table 1](#t1-copd-13-879){ref-type="table"}. For registered pharmacists, the average patient number with respiratory disease seen weekly and pharmacists' years of work experience were 7.98±3.566 and 7.61±7.585 years, respectively. The most common source of information about aerosol was undergraduate study (52.4%) followed by reading leaflets of the inhaler devices (22.4%). The most common answer about who trains patients on inhaler devices was "either the doctor or pharmacist" (54.1%). More than half of the registered pharmacists agreed that the primary obstacle in pharmaceutical care services was the lack of training (52.4%), followed by time constraints (39.4%). While for unregistered pharmacists, the most common sources of information obtained about aerosol use were undergraduate study (72.4%) followed by reading articles or specialized books (20.6%). The most common answer about who trains patients on inhaler devices was "nobody, but we provide written information" (47.6%).

Validation and reliability
--------------------------

For the reliability, the Cronbach's alpha test of internal consistency was 0.637 for the 24 items of KAT, and it is within the recommended acceptable result for reliability.[@b28-copd-13-879] The test--retest reliability of the 24 items of KAT indicated worthy reliability and stability of the instrument with Pearson's correlation coefficient of 0.440 (*P*\<0.05).

Regarding item analysis for KAT, the item difficulty index for most items was between 0.130 and 0.667, which is satisfactory ([Table 2](#t2-copd-13-879){ref-type="table"}). No item scored above 0.70 (which indicated that most of the subjects answered these questions incorrectly) and two items (item 3, 22) had low difficulty index below 0.20. However, these two items were retained as they reflected basic knowledge regarding aerosol therapy administration technique and use. The corrected item-total correlation (point biserial correlation) values ranged from 0.115 to 0.361 ([Table 2](#t2-copd-13-879){ref-type="table"}). Although 12 items (item 1, 3, 4, 5, 7, 8, 13, 16, 17, 18, 19, and 23) showed corrected item-total correlation value of less than 0.20, all items appeared to be suitable for retention depending on the meaningfulness of the items and the study design's scientific point of view. Ferguson's sigma for the questionnaire was 0.948, which is considered perfect.

Knowledge of aerosol
--------------------

[Table 3](#t3-copd-13-879){ref-type="table"} shows the correct answer percentage of KAT and its two subscales. The total KAT scores for registered and unregistered pharmacists were 10.13±3.152 and 8.29±2.930, respectively, which revealed inadequate pharmacist knowledge of inhaled therapies and technique. In addition, only 38.38% of the total sample was found to have high KAT level scores. The results showed that the registered pharmacists had a higher total KAT and its subscales scores than unregistered pharmacists (*P*\<0.01).

The results showed a higher proportion of KAT scores among male pharmacists with a family history of respiratory diseases and pharmacists with a master's degree (*P*\<0.05). Furthermore, pharmacists with a postgraduate degree and who read leaflets accompanying inhaler devices had higher total KAT scores than pharmacists who read articles or books specialized in the field (*P*\<0.05). Additionally, there were significant differences in the total KAT score according to the pharmacists' attitude regarding who trains the patient on inhaler device use (*P*\<0.05). Finally, the results showed insignificant associations between total KAT score and university type, employment status, pharmacy or hospital location area, and primary obstacles in pharmaceutical care services (*P*\>0.05). There were significant associations between the pharmacist type and some of KAT questions (3, 7, 11, 14, 16, 17, 19, 20, 21, and 23, *P*\<0.05). The results showed that the registered pharmacists had a higher correct answer response for these questions than unregistered pharmacists. [Table 4](#t4-copd-13-879){ref-type="table"} shows the percentage of correct response and incorrect response of each question of KAT among the sample population.

Pharmaceutical care practice
----------------------------

[Table 5](#t5-copd-13-879){ref-type="table"} shows pharmaceutical care practice questionnaire results of registered community pharmacists in Iraq. The pharmaceutical care practice scores of registered pharmacists were moderate (12.42±3.258) and only 22.90% had low practice scores. There were significant differences between pharmaceutical care practice and the university type (higher scores with government university \[*P*\<0.05\]), and the pharmacists' attitude (pharmacists who train patients on inhaler device use had higher practice scores than others \[*P*\<0.05\]).

KAT and pharmaceutical care practice correlations
-------------------------------------------------

For the registered pharmacists, there were positive correlations between the total KAT score and the total pharmaceutical care practice score (*r*=0.196, *P*\<0.05) and the average number of patients with a respiratory disease seen weekly by the pharmacist (*r*=0.463, *P*\<0.01). Moreover, there were positive correlations between total KAT score and aerosol administration technique subscale with pharmacotherapy care practice (*r*=0.188, *P*\<0.05 and *r*=0.239, *P*\<0.01, respectively) and comorbid disease management care practice (*r*=0.208, *P*\<0.01 and *r*=0.179, *P*\<0.05, respectively) ([Table 6](#t6-copd-13-879){ref-type="table"}). The knowledge of aerosol medicine use subscale was positively correlated only with comorbid disease management care practice (*r*=0.154, *P*\<0.05). There were significant correlations between KAT total score with both knowledge of aerosol administration technique subscale (*r*=0.680) and knowledge of aerosol medicine use subscale (*r*=0.814), (all *P*\<0.01). In addition, there was a significant correlation between KAT subscales (*r*=0.162, *P*\<0.01). Furthermore, a significant association was found between KAT levels (high and low) and practice levels (high and low) (*P*\<0.05).

Discussion
==========

All health care professionals have the responsibility to ensure that patients take their medications correctly, especially aerosol medications. Nowadays, there are a lot of aerosol devices that enhance patients' adherence to medication but instructions on how to use them is still the responsibility of the health care professional at each visit.

Many studies have shown that registered pharmacists were inadequately demonstrating aerosol medication technique.[@b23-copd-13-879],[@b29-copd-13-879]--[@b31-copd-13-879] However, no study has focused on aerosol knowledge of unregistered pharmacists or the effect of aerosol knowledge on pharmaceutical care practice or diverse inhaler device knowledge technique.

The KAT questionnaire showed good validity and reliability and is suitable for use for training purposes. This study showed a low level of knowledge regarding aerosol administration and medication use among both registered and unregistered pharmacists. Many factors affected participants' knowledge, eg, gender, a family history of asthma or COPD, educational level, and source of information. A previous report showed gender, age, years of work experience did not affect pharmacists' aerosol knowledge.[@b32-copd-13-879] In contrast, these factors did not affect the pharmaceutical care practice of the registered pharmacists. Moreover, the results showed that work experience had no effect on the pharmaceutical care practice, which is inconsistent with a previous report.[@b33-copd-13-879] This may be due to lack of training, as 52% of the participants showed that lack of training is the primary obstacle, even though the result was insignificant. As a consequence, low level of knowledge directly affects the pharmaceutical care practice among Iraqi pharmacists as there was a positive correlation between them as mentioned previously. The results showed that the average patient number had a positive correlation with the KAT and the practice scores, respectively. This means that the number of patients who seek advice is a motivating factor for pharmacists to increase their knowledge regarding aerosol and pharmaceutical care practice. However, the overall knowledge and practice scores in the sample population were low and medium, respectively. Therefore, changing ways of education and training can improve the overall knowledge and practice to enable better service to the community.[@b34-copd-13-879]--[@b37-copd-13-879] Also, it was found that collaboration between the health care providers can enhance the overall outcome of the patients.[@b36-copd-13-879],[@b38-copd-13-879]

A previous report showed that pharmacists' professional performance was under-appreciated by the Iraqi society as only 20.20% of the sample population showed that the knowledge of the pharmacist will lead them to choose a particular community pharmacy.[@b39-copd-13-879] This is due to the lack of advice and information they received from the pharmacists. Ibrahim et al's study supports our findings that a low KAT score of pharmacists will affect the pharmacists' practice professionally and finally patients' attitude toward the pharmacists' role in the community. Another study showed that a high level of pharmaceutical care practice enhanced patients' appreciation.[@b33-copd-13-879] Therefore, to enhance the knowledge and pharmaceutical care regarding any disease, Iraqi colleges should either offer OSCE exams and increase the total credits of the clinical pharmacy and therapeutic subjects or offer a Pharm-D program which is more oriented to patient care and pharmaceutical practice. For example, in Iraq, the students are taught chemistry (chemistry and pharmaceutical chemistry) for ten semesters (5 years), while for clinical pharmacy subjects it is only 2 years (four semesters, starting from 4th and 5th years). Every community pharmacist should be an expert in pharmaceutical care, pharmacotherapy, and health promotion and have good communication skills. Thus, it is important that the pharmacy courses offered in Iraq keep up with the rising demands of patient-centered health care.

In Iraq, it is important to include training exams or continuous educational programs (like continuing professional development and continuing pharmacy education) offered by the SIP or any official institutes as a prerequisite to becoming a licensed registered pharmacist. The Ministry of Health offers a free of charge Clinical Pharmacy Program, but not for all unregistered pharmacists (only for top ten graduates).[@b40-copd-13-879] Overall, these programs will increase the pharmacists' knowledge, attitude, and practice toward pharmaceutical care.[@b34-copd-13-879],[@b41-copd-13-879] An alternative option is to focus on educational research with emphasis on the objective measures of clinical professional performance, so as to improve pharmacy education and residency training.[@b34-copd-13-879]

Conclusion
==========

Using a validated tool to evaluate the knowledge and practice of health care professionals is an important step to improve the whole educational process or enhance pharmaceutical care. The KAT showed good validity and reliability, hence, it can be used for training or educational purposes. This study showed that professional knowledge and pharmaceutical care are a major concern in Iraq. Its implementation depends on the whole educational process from undergraduate study to residence training.
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###### 

The demographic data of registered and unregistered community pharmacists in Iraq

  Variables                                                                                 Registered pharmacist (N=170)   Unregistered pharmacist (N=170)   Total KAT score (N=340)
  ----------------------------------------------------------------------------------------- ------------------------------- --------------------------------- -------------------------
  Age (years)                                                                               31.62±8.661                     24.75±2.554                       8.92±3.188
  Average number of patients with COPD seen weekly                                          7.98±3.566                      --                                
  Work experience (years)                                                                   7.61±7.585                      --                                
  Gender                                                                                                                                                      
   Male[a](#tfn2-copd-13-879){ref-type="table-fn"}                                          52.4%                           35.3%                             9.40±3.029
   Female                                                                                   47.6%                           64.7%                             8.54±3.265
  University type                                                                                                                                             
   Government                                                                               81.2%                           31.8%                             9.11±3.08
   Private                                                                                  18.8%                           68.2%                             8.67±3.316
  Education level                                                                                                                                             
   Bachelor's degree                                                                        89.4%                           100%                              8.82±3.168
   Diploma                                                                                  8.8%                            --                                10.40±2.898
   Master's degree                                                                          1.8%                            --                                12.00±4.583
  Family/personal history of respiratory disease                                                                                                              
   Yes                                                                                      28.2%                           15.9%                             9.56±3.477
   No                                                                                       71.8%                           84.1%                             8.74±3.084
  Employment status                                                                                                                                           
   Private                                                                                  24.7%                           --                                9.31±2.892
   Government                                                                               21.2%                           --                                9.17±3.094
   Both                                                                                     54.1%                           --                                10.28±3.128
  Pharmacy or hospital location                                                                                                                               
   Rural                                                                                    17.6%                           --                                9.50±2.910
   Urban                                                                                    82.4%                           --                                9.87±3.134
  Information obtained on aerosol use                                                                                                                         
   Undergraduate study                                                                      52.4%                           72.4%                             8.91±3.123
   Postgraduate study[b](#tfn3-copd-13-879){ref-type="table-fn"}                            8.8%                            0                                 10.38±2.68
   Attending meeting, course, workshop                                                      4.1%                            7.1%                              9.89±3.195
   Reading article or specialized book[b](#tfn3-copd-13-879){ref-type="table-fn"}           6.5%                            20.6%                             7.74±3.448
   Reading leaflet accompanying inhaler device                                              22.4%                           0                                 9.55±3.073
   Directly from personal clinical experience and common sense                              5.9%                            0                                 7.90±2.961
  Who trains the patient on inhaler device use?                                                                                                               
   Pharmacist[b](#tfn3-copd-13-879){ref-type="table-fn"}                                    26.5%                           44.7%                             9.08±2.960
   Doctor                                                                                   13.5%                           4.7%                              9.32±2.833
   Either the doctor or pharmacist, it depends[a](#tfn2-copd-13-879){ref-type="table-fn"}   54.1%                           2.4%                              9.50±3.129
   Nobody, but we provide written information                                               2.4%                            47.6%                             7.73±3.339
   Nobody, and we do not give written information                                           3.5%                            0.6%                              10.86±4.059
  Primary obstacle in pharmaceutical care services                                                                                                            
   Time constraints                                                                         39.4%                           --                                10.15±3.006
   Lack of training                                                                         52.4%                           --                                9.83±3.076
   Lack of reimbursement                                                                    8.2%                            --                                8.00±3.187

**Notes:** Data presented as mean ± standard deviation or percentage. Significant difference between groups,

*P*\<0.001;

*P*\<0.05.

**Abbreviation:** KAT, Knowledge of Aerosol Tool.

###### 

Psychometric properties of the KAT by item analysis (N=340)

  Question number   Mean ± SD     Difficulty index   Point biserial correlation[\*](#tfn5-copd-13-879){ref-type="table-fn"}   Cronbach's alpha if item deleted
  ----------------- ------------- ------------------ ------------------------------------------------------------------------ ----------------------------------
  Question 1        2.53±1.085    0.460              0.144                                                                    0.634
  Question 2        2.40±1.004    0.284              0.235                                                                    0.624
  Question 3        2.30± 1.033   0.189              0.162                                                                    0.632
  Question 4        2.29±1.161    0.278              0.156                                                                    0.633
  Question 5        2.40±1.147    0.284              0.124                                                                    0.636
  Question 6        1.82±1.058    0.573              0.235                                                                    0.624
  Question 7        2.29±1.238    0.248              0.168                                                                    0.632
  Question 8        2.17±1.248    0.514              0.115                                                                    0.639
  Question 9        1.91±1.061    0.532              0.278                                                                    0.619
  Question 10       2.51±1.169    0.278              0.226                                                                    0.625
  Question 11       2.35±1.286    0.455              0.313                                                                    0.613
  Question 12       2.37±1.228    0.413              0.361                                                                    0.608
  Question 13       2.18±0.727    0.644              0.136                                                                    0.633
  Question 14       2.26±0.881    0.455              0.260                                                                    0.623
  Question 15       1.99±1.137    0.207              0.236                                                                    0.624
  Question 16       1.79±0.801    0.508              0.164                                                                    0.631
  Question 17       1.86±0.931    0.449              0.136                                                                    0.634
  Question 18       2.31±1.141    0.390              0.120                                                                    0.637
  Question 19       2.29±1.060    0.384              0.153                                                                    0.633
  Question 20       1.80±1.139    0.667              0.249                                                                    0.622
  Question 21       2.22±1.040    0.502              0.332                                                                    0.614
  Question 22       2.19±1.125    0.130              0.298                                                                    0.617
  Question 23       2.68±0.799    0.638              0.133                                                                    0.634
  Question 24       2.40±1.044    0.319              0.231                                                                    0.624

**Note:**

Corrected item-total correlation.

**Abbreviation:** KAT, Knowledge of Aerosol Tool.

###### 

Descriptive and correct answer percentages for KAT and its subscales

  Characteristics   KAT          Knowledge of aerosol administration techniques subscale   Knowledge of aerosol medicine use subscale                                                                    
  ----------------- ------------ --------------------------------------------------------- -------------------------------------------- ------------ ------------ ------------ ------------ ------------ ------------
  Mean ± SD         9.21±3.175   10.13±3.152                                               8.29±2.930                                   4.18±1.885   4.41±1.954   3.95±1.788   5.03±2.248   5.72±2.085   4.35±2.201
  Potential range   0--24        0--24                                                     0--24                                        0--12        0--12        0--12        0--12        0--12        0--12
  Correct answer    38.38%       42.21                                                     34.54%                                       34.83%       36.75        32.91%       41.92%       47.67        36.25%

**Abbreviation:** KAT, Knowledge of Aerosol Tool.

###### 

KAT answer frequencies (N=340)

  KAT                                                                                                                                                                Registered pharmacist (N=170)   Unregistered pharmacist (N=170)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------- ---------------------------------
  1\. The most important advice the pharmacist can give the patient for correct pressurized metered dose inhaler (pMDI) use is                                                                       
   a. Shake the device before inhalation.                                                                                                                            34.7%                           20.6%
   b. Exhale deeply before inhalation.                                                                                                                               10%                             11.2%
   **c. Firing the device after beginning inspiration**.                                                                                                             40%                             46.5%
   d. Inhale deeply and forcefully.                                                                                                                                  15.3%                           21.8%
  2\. When using the pMDI, a rapid inspiration is recommended                                                                                                                                        
   a. True.                                                                                                                                                          30%                             18.8%
   **b. False**.                                                                                                                                                     27.1%                           22.9%
   c. Depend on the patient status.                                                                                                                                  32.9%                           40.6%
   d. I do not know.                                                                                                                                                 10%                             17.6%
  3\. How long do you tell patients to wait before taking a second puff?[\*](#tfn9-copd-13-879){ref-type="table-fn"}                                                                                 
   a. At least 5 seconds.                                                                                                                                            23.5%                           27.6%
   b. At least 10 seconds.                                                                                                                                           38.8%                           32.4%
   **c. At least 20 seconds**.                                                                                                                                       29.4%                           14.1%
   d. I do not know.                                                                                                                                                 8.2%                            25.9%
  4\. How long do you tell patients to hold their breath for after taking a puff?                                                                                                                    
   a. At least 4 seconds.                                                                                                                                            35.9%                           35.9%
   b. At least 6 seconds.                                                                                                                                            24.1%                           15.3%
   **c. At least 8 seconds**.                                                                                                                                        26.5%                           20.6%
   d. I do not know.                                                                                                                                                 13.5%                           28.2%
  5\. Which of these sentences about spacers for metered dose inhalers is correct?                                                                                                                   
   **a. They can be used regardless of the patient's age**.                                                                                                          29.4%                           27.6%
   b. If the patient is cooperative, it is better to administer the drug directly in the mouth.                                                                      25.3%                           30.0%
   c. They have to be washed once a day.                                                                                                                             22.9%                           14.7%
   d. I do not know.                                                                                                                                                 22.4%                           27.6%
  6\. How often do you tell patients to clean their spacer?                                                                                                                                          
   **a. After each use**.                                                                                                                                            51.2%                           54.7%
   b. Every day.                                                                                                                                                     25.3%                           24.7%
   c. Every week.                                                                                                                                                    9.4%                            8.2%
   d. I do not know.                                                                                                                                                 14.1%                           12.4%
  7\. The most important step for correct dry powder inhaler (DPI) inhalation is:[\*\*](#tfn10-copd-13-879){ref-type="table-fn"}                                                                     
   a. Shake the device before inhalation.                                                                                                                            42.9%                           38.2%
   b. Exhale deeply before inhalation.                                                                                                                               18.2%                           13.5%
   c. Firing the device after beginning inspiration.                                                                                                                 4.1%                            31.8%
   **d. Inhale deeply and forcefully**.                                                                                                                              34.7%                           16.5%
  8\. How often do you tell patients to clean their DPI mouth piece?                                                                                                                                 
   **a. After each use**.                                                                                                                                            49.4%                           42.4%
   b. Every day.                                                                                                                                                     23.5%                           8.2%
   c. Every 2 to 3 weeks.                                                                                                                                            13.5%                           13.5%
   d. I do not know.                                                                                                                                                 13.5%                           35.9%
  9\. It is OK if the patient does not feel the DPI powder go down.                                                                                                                                  
   **a. True**.                                                                                                                                                      43.5%                           52.4%
   b. False.                                                                                                                                                         24.7%                           27.1%
   c. Depends on the DPI apparatus.                                                                                                                                  22.4%                           4.1%
   d. I do not know.                                                                                                                                                 9.4%                            16.5%
  10\. How much time can pass between solution placed in the nebulizer and its administration?                                                                                                       
   **a. Ten minutes**.                                                                                                                                               29.4%                           25.9%
   b. No more than 1 h.                                                                                                                                              12.9%                           30.0%
   c. It is irrelevant.                                                                                                                                              24.1%                           21.8%
   d. I do not know.                                                                                                                                                 33.5%                           22.4%
  11\. How often should the nebulizer bulb be washed?[\*](#tfn9-copd-13-879){ref-type="table-fn"}                                                                                                    
   **a. After each use**.                                                                                                                                            47.6%                           31.8%
   b. Once a day.                                                                                                                                                    21.2%                           13.5%
   c. Once a week.                                                                                                                                                   12.4%                           10.6%
   d. I do not know.                                                                                                                                                 18.8%                           44.1%
  12\. Spacer use results in a significant reduction in the amount of aerosol that is deposited in the mouth and throat.                                                                             
   **a. True**.                                                                                                                                                      32.9%                           39.4%
   b. False.                                                                                                                                                         17.6%                           18.2%
   c. Depends on the inhaler type.                                                                                                                                   25.9%                           11.2%
   d. I do not know.                                                                                                                                                 23.5%                           31.2%
  13\. When is the use of inhalational corticosteroids recommended?                                                                                                                                  
   a. In the majority of cases with viral or allergic wheezing.                                                                                                      15.3%                           8.2%
   **b. Only in cases with allergic wheezing or asthma**.                                                                                                            62.9%                           69.4%
   c. In bronchiolitis.                                                                                                                                              15.9%                           13.5%
   d. I do not know.                                                                                                                                                 5.9%                            8.8%
  14\. The purpose of using a corticosteroid inhaler is:[\*\*](#tfn10-copd-13-879){ref-type="table-fn"}                                                                                              
   a. To stop an asthma attack when it occurs.                                                                                                                       17.6%                           22.9%
   **b. To prevent asthma attacks**.                                                                                                                                 55.3%                           29.4%
   c. For immediate relief only when required.                                                                                                                       20%                             37.1%
   d. None of the above.                                                                                                                                             7.1%                            10.6%
  15\. Inhaled steroid effectiveness is improved by taking a β-agonist first.                                                                                                                        
   a. True.                                                                                                                                                          51.2%                           47.6%
   **b. False**.                                                                                                                                                     15.3%                           18.8%
   c. Depends on the dose of β-agonist.                                                                                                                              20.6%                           15.9%
   d. I do not know.                                                                                                                                                 12.9%                           17.6%
  16\. Corticosteroid inhalers should be taken:[\*\*](#tfn10-copd-13-879){ref-type="table-fn"}                                                                                                       
   a. When the patient feels an asthma attack coming on.                                                                                                             27.1%                           50.0%
   **b. At regular intervals**.                                                                                                                                      62.4%                           36.5%
   c. At least once weekly.                                                                                                                                          6.5%                            5.9%
   d. I do not know.                                                                                                                                                 4.1%                            7.6%
  17\. Improvement of patient's condition with the use of the corticosteroid inhalers:[\*\*\*](#tfn11-copd-13-879){ref-type="table-fn"}                                                              
   a. Is obtained immediately.                                                                                                                                       41.2%                           42.4%
   **b. May take 1 to 4 weeks**.                                                                                                                                     45.9%                           35.3%
   c. Is not noticeable.                                                                                                                                             5.3%                            10.6%
   d. None of the above.                                                                                                                                             7.6%                            11.8%
  18\. When starting corticosteroid, the patient should be concerned about which of the following regarding other medicine:                                                                          
   **a. Stopping other steroid medicine which can result in mental depression, weight loss, and/or muscle and joint pain**.                                          33.5%                           30.6%
   b. Changing the times other medicine is taken.                                                                                                                    22.9%                           30%
   c. Patient does not have to worry if he/she stops taking oral steroid since corticosteroid inhaler is also a steroid.                                             20.6%                           18.2%
   d. None of the above.                                                                                                                                             22.9%                           21.2%
  19\. The major advantage of using the corticosteroid inhalers is:[\*\*\*](#tfn11-copd-13-879){ref-type="table-fn"}                                                                                 
   **a. There are not as many side effects as with oral steroids**.                                                                                                  43.5%                           30.6%
   b. It is easier to remember to take inhaler medicine.                                                                                                             2.4%                            7.6%
   c. It works faster.                                                                                                                                               47.1%                           51.8%
   d. None of the above.                                                                                                                                             7.1%                            10.0%
  20\. It is important to advise the patient to rinse his/her mouth out or gargle after inhaled corticosteroid use:[\*\*](#tfn10-copd-13-879){ref-type="table-fn"}                                   
   **a. True**.                                                                                                                                                      72.9%                           51.8%
   b. False.                                                                                                                                                         7.6%                            10.6%
   c. Gargle but not every time.                                                                                                                                     11.2%                           17.6%
   d. I do not know.                                                                                                                                                 8.2%                            20.0%
  21\. When is ipratropium bromide recommended?[\*\*](#tfn10-copd-13-879){ref-type="table-fn"}                                                                                                       
   a. Instead of salbutamol.                                                                                                                                         21.8%                           27.1%
   **b. Together with salbutamol in cases of severe wheezing**.                                                                                                      66.5%                           32.9%
   c. Never.                                                                                                                                                         2.4%                            7.6%
   d. I do not know.                                                                                                                                                 9.4%                            32.4%
  22\. When is aerosol therapy with mucolytics recommended?                                                                                                                                          
   a. In various cases of upper and lower respiratory tract infections.                                                                                              42.9%                           26.5%
   b. Only in the case of acute bronchitis or pneumonia.                                                                                                             38.8%                           24.7%
   **c. Almost never**.                                                                                                                                              9.4%                            16.5%
   d. I do not know.                                                                                                                                                 8.8%                            32.4%
  23\. What is the first-choice treatment for respiratory distress?[\*](#tfn9-copd-13-879){ref-type="table-fn"}                                                                                      
   a. Mucolytic aerosol.                                                                                                                                             8.2%                            14.1%
   b. Inhaled corticosteroid aerosol.                                                                                                                                18.8%                           20.6%
   **c. Salbutamol aerosol**.                                                                                                                                        67.6%                           51.2%
   d. I do not know.                                                                                                                                                 5.3%                            14.1%
  24\. Which of the following is true when salbutamol aerosol is used for bronchiolitis?                                                                                                             
   a. It should be used until obtaining a clinical cure.                                                                                                             18.8%                           26.5%
   **b. It should only be continued in the case of a positive response**.                                                                                            36.5%                           31.8%
   c. It should be used together with corticosteroid inhaler.                                                                                                        28.8%                           18.2%
   d. I do not know.                                                                                                                                                 15.9%                           23.5%

**Notes:** Correct answers appear in bold; significant association

*P*\<0.01,

*P*\<0.001,

*P*\<0.05.

**Abbreviation:** KAT, Knowledge of Aerosol Tool.

###### 

Appropriate pharmaceutical care practice regarding inhaled therapy among registered community pharmacists in Iraq (N=170)

  Pharmaceutical care practice                     Never   Rarely   Often   Always
  ------------------------------------------------ ------- -------- ------- --------
  1\. Do you assess patient inhaler skill use?     5.3%    30%      24.1%   40.6%
  2\. Do you assess sick day management?           16.5%   35.9%    28.8%   18.8%
  3\. Do you assess pharmacotherapy?               14.1%   30.6%    35.9%   19.4%
  4\. Do you assess comorbid disease management?   14.1%   34.7%    31.2%   20.0%
  5\. Do you assess healthy living choices?        4.7%    11.2%    47.1%   37.1%

###### 

Correlation matrix between pharmaceutical care practice and knowledge of aerosol tool (N=170)

  Characteristics                              Total KAT score                                        Knowledge of aerosol administration techniques subscale   Knowledge of aerosol medicine use subscale
  -------------------------------------------- ------------------------------------------------------ --------------------------------------------------------- ------------------------------------------------------
  Total KAT                                    --                                                     0.680[\*\*](#tfn14-copd-13-879){ref-type="table-fn"}      0.814[\*\*](#tfn14-copd-13-879){ref-type="table-fn"}
  Do you assess patient inhaler skill use?     0.133                                                  0.033                                                     0.141
  Do you assess sick day management?           0.117                                                  0.111                                                     0.084
  Do you assess pharmacotherapy?               0.188[\*](#tfn13-copd-13-879){ref-type="table-fn"}     0.239[\*\*](#tfn14-copd-13-879){ref-type="table-fn"}      0.063
  Do you assess comorbid disease management?   0.208[\*\*](#tfn14-copd-13-879){ref-type="table-fn"}   0.179[\*](#tfn13-copd-13-879){ref-type="table-fn"}        0.154[\*](#tfn13-copd-13-879){ref-type="table-fn"}
  Do you assess healthy living choices?        0.092                                                  0.029                                                     0.150

**Note:**

*P*\<0.05,

*P*\<0.01.

**Abbreviation:** KAT, Knowledge of Aerosol Tool.
